Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy
and biological activity of intraperitoneal GEN-1 plus NACT compared to NACT alone.